Cephalothin sodium, also designated cefalotin sodium in international pharmacopoeias, is handled as a moisture-sensitive β-lactam in the production of sterile dry-powder veterinary injectables. The sodium salt is dissolved in chilled water for injection and passed through a 0.22 µm sterilising-grade membrane in an isolator rated ISO 14644-1:2015 Class 5 in operation; terminal steam sterilisation at 121°C for 15 min is not considered chemically robust because the β-lactam ring opens to desacetyl cefalotin and thienylacetic acid-related substances. The solution is lyophilised in partially stoppered Type I borosilicate glass vials; the freeze-dryer shelf temperature is ramped below the formulation-specific collapse temperature determined by freeze-drying microscopy, and the primary drying chamber pressure is maintained to sustain sublimation without cake collapse. The product is sealed with chlorobutyl stoppers under nitrogen to keep headspace oxygen below 2%. The finished powder is tested for water content by Karl Fischer per USP <921>, sterility per USP <71>, bacterial endotoxins per USP <85>, and sub-visible particulate matter per USP <788>; assay and related substances are measured by a stability-indicating HPLC method that resolves cefalotin from hydrolytic degradants. The endotoxin limit is derived from the maximum dose per kilogram, and for a parenteral product intended for horses or dogs the release limit is calculated below 0.25 EU/mg, though the exact value must be registered for the target species and route.

Fill weight control in the aseptic suite is maintained with a 100% checkweigher because the powder is light and electrostatic; auger and vacuum-drum dosing systems are preferred over gravity filling for poor-flowing lyophilised cake. When the powder accumulates static charge, it bridges in the hopper and produces weight drift across the filling campaign; the line speed is therefore reduced and the relative humidity is kept below 25% RH to dissipate charge. The granulation or crystallisation process that generated the API determines the particle size distribution, and oversized particles above 250 µm are removed by sieving because they do not dissolve quickly in sterile water. Reconstitution time is measured by injecting water into the vial and agitating until the cake dissolves; a typical internal limit is less than 2 min, but the registered specification may differ by product. The sealing machine is set to apply stopper compression that prevents gas exchange without distorting the rubber; regular checks are performed with a residual seal force tester and visual inspection for cracked glass and loose crimps. For depot or large-volume injectable formats, the vial neck is checked for lyophilised powder carryover because residual API around the stopper seat may later hydrolyse and alter the appearance of the reconstituted solution.

Why do soluble cefalotin granules require granulation moisture control rather than simple blending?

Drinking-water medication is a high-volume route for poultry and swine, but cefalotin sodium is not stable enough to be dry-blended with dextrose and packed directly into foil-lined sachets. The material agglomerates when the blend rises above a water activity of 0.6, and free water catalyses ring opening. Fluid-bed granulation with a top-spray nozzle is used to produce free-flowing granules with a mass median particle diameter between 180 µm and 425 µm; the inlet air temperature is held below the degradation point demonstrated by differential scanning calorimetry, commonly below 45°C, and the binder is either an aqueous solution sprayed under high drying capacity or an ethanolic system when the API supplier specifies non-aqueous processing. Granules are screened through 20-mesh and 40-mesh sieves; the undersize fraction below 150 µm is recycled to the granulator, and the final moisture specification is based on registration stability data. The granule bed in a fluid bed may defluidise if the spray rate is too high, and the resulting wet mass produces lumps that fail the dissolution test in field water. Batch-to-batch variance in granule porosity is a known processing bottleneck because it changes the wetted surface area and therefore the stock solution preparation time in the field.

Stock solution behaviour rather than bulk assay controls the field utility of soluble granules. The product is dispersed in a fixed volume of water, typically 10 g/L to 50 g/L, and then dosed by a proportioner pump at 1% to 5% into the drinking line. In hard water containing 300 ppm calcium carbonate, the solution may become cloudy or leave a residue on nipple drinkers; sodium citrate is added as a chelating agent, and dissolution is tested in both pH 6.8 phosphate buffer and cold hard water at 15°C and 25°C. The finished stock solution pH is controlled to avoid pump diaphragm damage; an acidic pH below 4.0 can stress silicone tubing in metering equipment. Because the medication is ingested orally, the granule is not sterile; microbial enumeration and absence of specified organisms are tested per USP <61> and USP <62>, and the water activity specification is set low enough to prevent mould growth during shelf life. The granule packaging line is operated in a low-humidity area, and the sachet material is a multi-layer foil laminate because water-vapour transmission through polyethylene-only packaging shortens the assigned retest period.

Regulatory approval for oral cephalothin in food-producing species is not universal. In the European Union, unless cefalotin is listed in the applicable maximum residue limit legislation under Regulation (EU) No 37/2010, administration to food-producing animals is precluded; the target species approval is the controlling document. Formulation work may therefore be intended for non-food equine or companion animal protocols, or for regulatory submission in a jurisdiction where the residue file is accepted. If the product is approved for a food-producing species, the withdrawal period derives from residue depletion data in that species and is not transferable from another cephalosporin. Equipment carryover is also a critical control point; beta-lactam residues on shared granulation and packaging equipment are removed with alkaline cleaning agents and verified by a validated swab method with an HPLC limit of detection below 1 ppm in the next non-antibiotic batch. The cleanability of the fluid-bed product filter bags is documented because retained cefalotin dust can contaminate subsequent batches and cause cross-contamination failures during regulatory inspection.

Feed premix application is constrained by β-lactam instability in pelleted feeds. The free sodium salt is not simply adsorbed onto corn cob or rice hulls because water activity above 0.6 accelerates hydrolytic ring opening; after steam conditioning at 75–85°C for 30 s, assay loss can exceed the registered specification unless the cefalotin is protected. If a premix is required, the API is first dry-blended with microcrystalline cellulose and a hydrophobic binder in a ribbon blender, then the admixture is coated with hydrogenated vegetable oil to slow moisture uptake. The coated premix is incorporated at low inclusion rates because the active dose is small and segregation risk increases when the API particle size distribution is narrow. Published data for this specific configuration is limited, and the route is not a first-choice delivery form. In most jurisdictions, cefalotin is not approved for feed premix in food-producing animals; the premix discussion therefore applies to non-food species, zoo or wildlife protocols, or research facilities where the animal is not entering the human food chain. If a feed premix is produced for an approved market, the batch is released under 21 CFR 211.165 or the equivalent, with finished feed assay, homogeneity, and stability at 25°C/60% RH.

When oral cefalotin is selected in companion animal compounding, acid protection defines the granulation route

Oral cefalotin is not pharmacokinetically interchangeable with cephalexin, because the first-generation cephalosporin is poorly absorbed from the canine and feline stomach where gastric fluid pH is below 2.0. The tablet or capsule form therefore has a narrow therapeutic scope: it may be selected for local gastrointestinal effect in a species where injectable dosing is not feasible. In the manufacturing sequence, wet granulation with water is avoided because residual moisture after drying leaves the API in an amorphous state, which increases the degradation rate. Roller compaction is used to produce granules with a bulk density between 0.55 g/cm³ and 0.70 g/cm³, and the compacted ribbons are milled through 12-mesh or 16-mesh screens. The granules are blended in a V-blender at 60% fill volume with sodium starch glycolate and microcrystalline cellulose; magnesium stearate is added at the final lubrication step for 2–4 min, because longer mixing reduces dissolution by forming a hydrophobic film on the granules.

Tablet compression is performed on a rotary tablet press at a compression force sufficient to give a tablet breaking force by USP <1217> consistent with a friability not exceeding 1.0%. The disintegration requirement is established according to USP <701>; if an enteric coating is applied to protect the β-lactam from gastric acid, a delayed-release dissolution test is used instead of immediate-release disintegration. Coating systems are selected from aqueous polyacrylate or cellulose-based dispersions, and the coating pan is operated at an inlet air temperature below 40°C to limit thermal damage. For capsules, the roller-compacted granules are filled into hard gelatin or hypromellose capsules on an automatic capsule filler fitted with a vacuum dosing disc; the fill weight is monitored at 100% checkweighing because cefalotin sodium is light and electrostatic. Capsule shell brittleness becomes a defect risk when the filling suite humidity is below 30% RH, so the shell is conditioned before filling and the bulk granule is stored in a sealed bin until use.

Release testing for oral solids must include assay, related substances, dissolution, moisture, and microbial enumeration per USP <61> and USP <62>. Dissolution is run in 900 mL of pH 6.8 phosphate buffer with paddles at 50 rpm if the product is not enteric-coated; the acceptance criterion is registered per the approved application. In practice, oral solid formulations of cefalotin are rarely scaled beyond pilot level because the effective dose and instability make the product less favourable than cephalexin or cefadroxil; if a batch is produced, the operations are carried out in a low-humidity suite with RH below 30% and the product is packaged in cold-form aluminium foil blisters. The foil blister cavity is sized to minimise headspace, and a desiccant pouch is included if stability data show moisture uptake above 2.0% at 40°C/75% RH. The printed foil is rejected if the seal integrity test fails, because pinholes admit moisture and lead to localised hydrolysis of the tablet surface during storage.

Prepared solutions of cefalotin sodium are generally extemporaneous rather than multi-dose finished products because the reconstituted solution degrades quickly at room temperature. The dry powder is dissolved in sterile water for injection to a concentration up to 100 mg/mL; the resulting solution is then transferred into 0.9% sodium chloride or 5% dextrose for intravenous infusion. Lactated Ringer's and high-pH electrolyte solutions are avoided unless compatibility has been demonstrated, because the higher pH accelerates hydrolysis and the solution can develop a yellow-to-amber tint. In-use stability is validated at 0, 2, 4 and 8 h by sampling for pH, colour, assay, and related substances; the solution is normally administered within 4 h at 22°C, and within 24 h if refrigerated at 2–8°C. The exact in-use window is registered in the prescribing information and depends on the diluent and container type; polyvinyl chloride and polyolefin containers may differ in sorption, and the line must be flushed before and after administration.

Production of a stable ready-to-use solution at industrial scale is possible only if the formulation is protected from oxygen and pH drift; this requires a sealed, oxygen-free manufacturing vessel and an aseptic filling line with temperature control. The solution is sterilised by membrane filtration, not by autoclaving; if a terminal sterilisation step is used, the resulting degradation products will exceed the specification and the sterility assurance cannot compensate for chemical instability. The closure system for a ready-to-use solution is a rubber stopper with an inert fluoropolymer coating; the vial is purged with nitrogen to reduce the headspace oxygen below 2%. The finished product is stored at 2–8°C and protected from light. Particulate matter is controlled by filtration and by a final in-line 0.22 µm membrane; the fill weight is checked with an automatic weight checker, and the fill volume is adjusted by the density of the solution at 20°C. Release of the solution form includes pH per USP <791>, osmolality, bacterial endotoxins per USP <85>, sterility per USP <71>, and insoluble particulate matter per USP <788>. If the solution is a non-sterile oral liquid rather than an injectable, the sterility tests are replaced by microbial enumeration per USP <61> and USP <62>, and the pH is adjusted with acetate or citrate buffers to a range compatible with palatability and chemical stability in the target species.